News & SEC Filings

View the latest news and SEC filings

News

LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024: Piper Sandler 36 th Annual Healthcare Conference Date:

LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 6:30 a.m. ET / 11:30 a.m.

Ohtuvayre™  (ensifentrine) launch recorded Q3 net sales of $5.6 million and  October net sales exceeded Q3 Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled across a broad COPD population Pipeline expansion continues: Phase 2 programs enrolling Conference

LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024 and host an investment community conference

SEC Filings

Date Form Filing Group

November 7, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

November 5, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

November 5, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

November 4, 2024

Report of unscheduled material events or corporate event

8-K

Current Reports

November 4, 2024

Quarterly report which provides a continuing view of a company’s financial position

10-Q

Quarterly Filings

November 1, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

November 1, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

November 1, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

November 1, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

Developing novel therapeutics for respiratory diseases

Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.